
Lukas Madl
Registered Technology Transfer Professional
Get their honest, personalized take on your startup.
Sign in to pitch Lukas →At a glance
- Full Name
- Lukas Madl
- Title
- Technology Transfer Manager / Head of Technology Transfer; Registered Technology Transfer Professional (RTTP)
- Firm
- tecnet equity (Tecnet Equity NÖ Technologiebeteiligungs-Invest GmbH)
- Firm Type
- Public/regional early-stage venture capital company owned by the State of Lower Austria (frequently indexed as an angel/seed investor for its very-early check activity)
- Investment Stage
- Pre-seed to Seed and early Series A (tecnet also offers a €50,000 SAFE for newly founded startups ahead of a first seed round)
- Check Size
- Very early SAFE of €50,000; seed rounds average roughly €2M (Series A rounds average ~€3M at the firm level)
- Target Company Profile
- Research-driven, high-tech startups and university spin-offs commercializing inventions from research labs
- Sector Focus
- Information & communication technologies (ICT), life sciences, industrial technologies, material sciences, and environmental technologies
- Geographic Focus
- Austria, with a strong mandate for Lower Austria (Niederösterreich)
- Location
- St. Pölten, Lower Austria, Austria
Background
Lukas Madl is a technology-transfer specialist at tecnet equity, the technology-investment company of the Austrian state of Lower Austria (founded 2002, headquartered in St. Pölten). He holds a degree in Genetics from the University of Vienna, pursued additional study in Geoinformatics while working, and has taken theology coursework in Vienna — a reflection of his stated interest in innovation ethics. He is certified as a Registered Technology Transfer Professional (RTTP).
His career spans research, public-sector, and industry roles. He began in clinical research at a major pharmaceutical company, then moved into product management, quality control, and customer support at a robotics-automation startup. At the Austrian Research Centers (Seibersdorf, now part of AIT), he handled international R&D cooperation and business development for satellite/earth-observation data products. He has also served as an external expert evaluating research and innovation projects for the European Commission.
At tecnet equity, Madl built and runs the "research-to-value" (r2v) program, which trains scientists and startup teams in open innovation, entrepreneurship, and intellectual property. His day-to-day work bridges research and market: advising scientists and researchers, assessing patents and technologies, developing innovation strategies, identifying applications and business partners, and negotiating licensing agreements. tecnet works closely with research organizations including the AIT Austrian Institute of Technology, the Austrian Academy of Sciences, BOKU (University of Natural Resources and Life Sciences), and the tribology competence center AC2T.
Madl describes tecnet's approach with the metaphor of "invention gardeners," tending young seedlings from research labs until they ripen into fruitful innovations, and he is particularly focused on innovation ethics — asking "what progress is truly good progress."
Investment Thesis & Focus
- Invests as part of tecnet equity in seed and early-stage deep-tech and research-based companies, especially those emerging from Austrian universities and research institutes.
- Sector breadth: ICT/software/AI, life sciences and biotech, industrial and material sciences, and environmental/climate technologies.
- Check profile: a fixed €50,000 SAFE convertible for very early (pre-first-seed) startups, scaling to seed rounds averaging roughly €2M and follow-on Series A participation.
- Regional mandate: a bridge "between research and market," with a clear preference for companies located in or willing to build in Lower Austria.
- What makes them say yes: strong underlying IP/technology, a credible path from lab invention to a market-ready product or business model, and founders open to structured support on entrepreneurship, IP, and open innovation.
Notable Investments
- Valanx Biotech — site-specific protein conjugation platform for antibody-drug conjugates (life sciences); Series A (~€7M, 2026).
- Ribbon Biolabs — high-throughput DNA synthesis technology (life sciences).
- Propcorn.ai — real-estate analytics platform for investment and broker decisions; seed rounds (2024–2026).
- Sipfront — telecom/VoIP test-automation platform; seed (Jan 2024) with a ~€500k co-lead follow-on (Jan 2026).
- Orderlion — B2B e-commerce/procurement platform connecting hospitality operators with suppliers; follow-on round.
- Nexufend — tecnet's most recent first-time investment (seed, 2025).
- eyeson — video-conferencing/webinar SaaS platform.
- Wikitude — mobile augmented-reality software; exited via acquisition.
- Exits: acquisitions include Wikitude, indoo.rs, and Sheepblue.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.